Glukóz Teva

Glukóz Teva is an intravenous solution that contains glucose monohydrate as its active ingredient. It is supplied in a sterile liquid form for infusion into the bloodstream. The product is manufactured for the European Union market and is used to provide a rapid source of glucose for metabolic needs. Glukóz Teva is typically packaged in single‑use containers suitable for hospital and clinical settings.

Glukóz Teva is administered intravenously to address acute or temporary needs for glucose. It is commonly employed in the following clinical situations:

- Treatment of hypoglycaemia when oral glucose is not feasible. - Provision of caloric support during peri‑operative fasting. - Management of metabolic demands in critically ill patients. - Support during prolonged intravenous nutrition regimens. - Stabilisation of blood glucose levels in patients receiving insulin therapy. - Adjunct therapy in certain diagnostic procedures requiring glucose infusion.

Glukóz Teva may cause a range of reactions, most of which are related to the rapid increase in plasma glucose. These effects are generally classified as follows:

Common: - Transient hyperglycaemia. - Local irritation at the infusion site. - Mild nausea or abdominal discomfort. - Headache associated with rapid glucose shifts.

Serious: - Severe hyperglycaemia leading to osmotic diuresis. - Electrolyte imbalances, particularly hyponatraemia. - Allergic reactions such as rash or urticaria. - Volume overload in patients with compromised cardiac function.

When using Glukóz Teva, healthcare professionals should consider several safety measures to minimise risk:

- Verify patient’s blood glucose level before administration. - Adjust infusion rate in patients with diabetes or impaired glucose tolerance. - Monitor electrolytes, especially sodium and potassium, during prolonged use. - Use caution in patients with renal or cardiac insufficiency due to fluid volume concerns. - Ensure aseptic technique to prevent contamination of the intravenous line. - Review medication history for agents that may potentiate hyperglycaemia.

Glukóz Teva can interact with other medications, requiring careful assessment:

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring. - Co‑administration with sulfonylureas in patients prone to hypoglycaemia.

Use with caution: - Beta‑blockers, which may mask hypoglycaemia symptoms. - Corticosteroids, which can increase glucose production. - Diuretics that affect electrolyte balance. - Medications that cause fluid retention, such as certain antihypertensives.